Dr. Weihua Jiang 蒋威华
Chief Physician, Lecturer
Department of Breast Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of benign and malignant breast tumors, with a focus on triple-negative breast cancer. Performs breast-conserving surgery, sentinel lymph node biopsy, and immediate stage I/II autologous or prosthetic breast reconstruction.
Dr. Jiang earned a master’s degree in oncology in 2009 and has worked in the Breast Surgery Department at Affiliated Cancer Hospital of Xinjiang Medical University since then. Research focuses on triple-negative breast cancer. Dr. Jiang leads three related projects, co-edited two books, and published over ten papers in core journals.
Professional roles
- Youth Committee Member, Breast Disease Branch, China International Exchange and Promotion Association for Medical and Healthcare
- Youth Committee Member, Oncologic Plastic Surgery Committee, China Anti-Cancer Association
- Member, Breast Cancer Professional Committee, Xinjiang Anti-Cancer Association
- Academic Committee Member, Chinese Journal of Health Emergency (Electronic Edition)
Name order: in Chinese the family name comes first (Jiang Weihua). Papers usually list the name as Weihua Jiang or Jiang W.
Selected publications
14 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int Immunopharmacol, 2026 (senior author): Exosomal circ_0005397 promotes TNBC progression by inducing M2 macrophage polarization via the miR-204-5p/STAT6 axis. PubMed 42308796
- Cancer Cell Int, 2026 (first author): Characterization of Circ_0048766: an oncogenic circular rna promoting triple-negative breast cancer progression via the miR-329-3p/CXCR4 axis and regulated by METTL3. PubMed 42399975
- Front Oncol, 2026 (senior author): Progression-free survival exceeding four years after transarterial embolization for liver metastases from triple-negative breast cancer: a case report. PubMed 42078808
- BMC Cancer, 2026 (senior author): Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events. PubMed 41555292
- Front Oncol, 2025 (senior author): A case report of multiple primary malignant tumors: breast cancer and colorectal cancer. PubMed 41378290
- Cancer Cell Int, 2023 (first author): Exosomal circRNA RHOT1 promotes breast cancer progression by targeting miR-204-5p/ PRMT5 axis. PubMed 37924099
- Front Oncol, 2021 (first author): MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study. PubMed 34123778
- Oncol Lett, 2020 (first author): Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. PubMed 32194678
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion